Trials / Completed
CompletedNCT00427362
A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 127 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To further assess the safety and effectiveness of adalimumab 40mg in the treatment PsA who have had an unsatisfactory response or intolerance to prior or ongoing DMARDs
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab |
Timeline
- Start date
- 2006-05-01
- Primary completion
- 2007-05-01
- First posted
- 2007-01-29
- Last updated
- 2008-05-02
Source: ClinicalTrials.gov record NCT00427362. Inclusion in this directory is not an endorsement.